Find Clinical Trial

Clinical acceptability of trimetazidine 80 mg once daily compared to trimetazidine 35 mg twice daily in patients with chronic stable angina pectoris: a multicentre randomised double blind study


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationCoronary Artery Disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

TRIMETAZIDINE,
S006795

Active Substance CodeS006795
Protocol CodeCL3-06795-008
ISRCTN CodeISRCTN84362208


Documents and links

Results summary READ MORE
Scientific publication READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility